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Summary The DNA stemline ploidy was measured by flow cytometry (FCM) in 129 samples from paraffin-
embedded primary testicular tumours (61 seminomas, 68 non-seminomas). Only one DNA stemline was found
in 38 seminomas and 44 non-seminomas. Two seminomas and one non-seminoma were DNA diploid, the
other tumours being non-diploid. Twenty-three seminomas and 24 non-seminomas displayed two or three
DNA stemlines. The median minimal DNA index (DI) of all seminomas was significantly higher than that of
all non-seminomas (1.58 vs 1.43; P: 0.008). Three seminomas removed from two monozygotic twins within I
week had DIs of 1.66, 1.56 and 1.59. In this limited series there was no association between DNA ploidy of
the primary tumour and the metastatic status for either seminomas or non-seminomas.
The results support the pathogenetic model stating that at least some (if not all) non-seminomas develop
from a seminoma by additional chromosomal aberration. The clinical relevance of DNA stemline ploidy has
to be further evaluated in larger series.
DNA flow cytometry (DNA FCM) has given clinically valu-
able information in several types of human solid tumours
(Tribukait, 1987; Kallioniemi et al., 1987; Kaern et al., 1990).
In general, non-diploid tumours and/or those tumours with a
high S-phase fraction are found to have a particularly high
malignant potential. The results from DNA FCM have also
contributed to the understanding of the pathogenesis, for
example, of human bladder cancer (Gustafson et al., 1982;
Tribukait, 1987).
DNA FCM measurements in samples from paraffin-em-
bedded formalin-fixed material (Hedley et al., 1983), enable
the study of even rare tumour types such as testicular cancer
(Sledge et al., 1987; FossA et al., 1991). The results have led
to interesting pathogenetic considerations, but the relevance
of DNA FCM in testicular cancer is still unclear.
The aim of the present study was to study the pathogenetic
and clinical relevance of flow-cytometric DNA analysis in
primary testicular cancer.
Patients and methods
One hundred and twenty-nine patients with histologically
proven testicular cancer were studied (Table I). Sixty-eight
patients had non-seminoma, either pure (44) or combined
with seminoma (24). Sixty-one patients had pure classical
seminoma. The patients were clinically staged according to
the Royal Marsden Hospital Classification System (Peckham
et al., 1979). All non-seminoma patients and 48 seminoma
patients had clinical stage I disease. The remaining 13
seminoma patients had clinical stage II (eight patients) or
stage III (five patients).
The patients were treated at the Norwegian Radium Hos-
pital according to previously described schedules (Fossa et
al., 1988): low-stage seminoma (stage I, IIA/B) received
abdominal radiotherapy (30-40 Gy/3-4 weeks). Advanced
stage seminoma patients were given 3-4 cycles of cisplatin-
based chemotherapy, most often followed by surgery or
radiotherapy. All non-seminoma patients underwent retro-
peritoneal lymph node dissection. If no metastases were
found histologically (pathological stage [PS] I), no further
treatment was given. If retroperitoneal lymph node metas-
tases were detected (PS II, 23 patients), three to four cycles
of chemotherapy were given post-operatively. Non-seminoma
Table I Patients' characteristics
Seminoma Non-seminoma
Combined Pure Total
No. ofpatients 61 24 44 68
Median age 36 33 28 30
Clinical stagea
I 48 24 44 68
>I 13
Pathological stage IIb 8 15 23
Subsequent distant met. 1 2 3
aNo metastases by clinical/radiological means; bRetropentoneal
lymph node metastases in the histopathological specimen from retro-
peritoneal surgery.
patients with retroperitoneal metastases (23 patients) and/or
those with subsequent distant metastases (three patients) were
grouped together as 'metastatic' non-seminoma patients (26
patients). Patients were followed up at 2-4 monthly intervals
after primary treatment. The median observation time for the
non-seminoma patients is currently 107 months and for the
seminoma patients 43 months.
Flow cytometry
Sections (100ym) were cut from paraffin blocks containing
well preserved tissue from the primary tumours. After
removal of the paraffin with xylol the tissue was hydrated as
previously desdribed (FossA & Thorud, 1986). Suspensions of
nuclei from the primary tumours were prepared (Hedley et
al., 1983) and stained with ethidium bromide (Jacobsen et al.,
1988). A laboratory built flow cytometer was used (Steen &
Lindmo, 1979). The FCM histograms were analysed with the
reference to the DNA indices (DIs) of identifiable stemlines
(Hiddeman et al., 1984). A diploid tumour had a DI of 1.0.
A tumour was regarded as non-diploid if at least one DNA
stemline had a DI different from 1.00. Tumours with only
one non-diploid stemline were discriminated from those with
multiple non-diploid stemlines. Tumours with DIs<0.90 and
those with DIs between > 1.10 and < 1.80 were regarded as
aneuploid. The tetraploid range comprised DI values between
1.80 and 2.20. The minimal/maximal DI of a tumour charac-
terised the range of DNA ploidies.
Contiguous 61gm sections served to evaluate the represen-
tativity of the material used for FCM. In large tumours,
sections from several paraffin blocks were histologically eval-
uated. In non-seminomas a block showing all the histological
elements was selected for flow cytometry.
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Statistics
Medians and ranges were calculated by the PC-based statis-
tical program package Medlog. Wilcoxon two sample tests
were used to evaluate the significance of differences between
distributions. P<0.05 was regarded as being statistically
significant.
Results
The median minimal DI was significantly higher for all
seminomas than for all non-seminomas (Table II) (P: 0.008).
Pure non-seminomas had the lowest median minimal DI
compared to seminomas (P: 0.004). There was a significant
difference between the median minimal DI for seminomas
and non-seminomas in tumours with only one DNA stemline
(P: (0.01).
The median maximal DIs were generally higher in non-
seminomas with two or three DNA stemlines than in semin-
omas. The limited number of cases within each subgroup did
not allow further statistical analysis.
Only one DNA stemline was identified in 38 of the 61
seminomas and in 44 of the 68 non-seminoma cases (Table
II, Figure 1). Two seminomas and one non-seminoma were
found to be diploid. Thirteen seminoma and 18 non-semin-
oma patients displayed two DNA stemlines, whereas three
DNA stemlines were observed in ten seminomas and six
non-seminomas (Figure 2).
The series contained three separate seminomas removed
from monozygotic twins within 1 week (One twin with
bilateral tumours, the other one with a unilateral tumour).
Interestingly the three seminomas displayed similar DNA
histograms with DIs of 1.66, 1.56 and 1.59 (Figure 3).
There was no association between DNA ploidy and metas-
tatic status in the seminomas or non-seminomas (Table III).
Discussion
We have previously demonstrated a satisfactory correlation
between the DIs derived from DNA FCM in fresh and
paraffin-embedded testicular cancer tissue (Fossa et al.,
1991). The technique cannot discriminate a difference
between stemlines of less than 10%. Diploid tumours should
therefore be regarded as 'near-diploid', with the individual
DI being 1.0±10%.
The estimation of the S phase fraction in paraffin-
embedded material is uncertain due to the relatively high
amounts of debris in the nuclear solutions, and therefore has
been omitted from the present study. In human cancer the S
phase may prove to be of greater clinical significance than
the DNA ploidy per se, as in patients with node-negative
breast cancer (O'Reilly et al., 1990).
Our results regarding DNA stemline ploidy in primary
testicular cancer are compatible with those published pre-
viously (Oosterhuis et al., 1989; Quirke et al., 1986;
Martineau, 1969; Nativ et al., 1989). The majority of the
tumours from the present study were non-diploid. Our results
also confirm Oosterhuis et al.'s (1989) finding of a signi-
ficantly higher median minimal DI in seminoma than in
non-seminoma. The most pronounced reduction of these DIs
is observed in pure non-seminomas as compared to semin-
omas while the combined tumours displayed intermediate
values.
In tumours with multiple DNA stemlines the range of the
DIs seems to be broader in non-seminomas (all cases com-
bined) than in seminoma, indicating a larger chromosomal
instability.
In Oosterhuis et al.'s (1989) series all seminomas displayed
only one DNA stemline, whereas non-seminomas could dis-
play multiple DIs. In contrast we observed multiple DNA
stemlines in 23 of 61 seminomas, i.e. at a similar proportion
as in non-seminomas. We have no explanation for the discre-
pancy between our series and that of Oosterhuis et al.
The significance of DNA ploidy in testicular cancer is
incompletely understood. Pierce and Abell (1972) developed
the hypothesis that seminomas and non-seminomas develop
separately from a pre-malignant condition. However, Fried-
man (1951); Raghavan et al. (1982) and Oliver (1987) sug-
gested that all invasive testicular germ cell tumours pass
through a stage of seminoma and then - by chromosome loss
- develop to a more aggressive non-seminoma. This hypo-
thesis is in agreement with Atkin's (1973) findings on
chromosomal numbers in testicular cancer. Also our and
Oosterhuis et al.'s (1989) observations on DNA ploidy in
testicular cancer support the view that non-seminomatous
tumours develop from seminoma by reduction of the DNA
index. Our results further indicate a larger chromosomal
instability in non-seminomas than in seminomas mirrored by
Table II DNA indices (DIs) in seminoma and non-seminoma
DI
Seminoma Non-seminoma
All tumours Combined Pure Total
61a 24 44 68
Minimal DI 1.58b,d 1.51 1.41d 1.43d
(1.0-3.09)c (0.82-2.58) (0.77-2.93) (0.77-2.93)
1 DNA stemline
38 15 29 44
Minimal DI 1.64d 1.57 1.47d 1.48d
(1.0-2.89) (1.27-2.32) (0.77-2.93) (0.77-2.93)
2 DNA stemlines
13 6 12 18
Minimal DI 1.61 1.49 1.35 1.39
(1.2-3.09) (1.17-2.58) (0.88-1.80) (0.88-2.58)
Maximal DI 1.79 2.58 2.52 2.55
(1.57-3.33) (2.15-3.45) (1.23-2.90) (1.22-3.45)
3 DNA stemlines
10 3 3 6
Minimal DI 1.15 1.39 1.33 1.33
(1.1-1.59) (0.88-1.45) (0.88-1.33) (0.82-2.08)
Intermediate DI 1.76 2.06 1.63 1.83
(1.36-2.58) (1.11-2.08) (1.22-2.03) (1.11-2.08)
Maximal DI 2.13 2.44 2.27 2.27
(1.72-3.08) (1.55-2.85) (1.48-3.20) (1.48-3.10)
aNumber ofpatients; bMedian;cRange;dSignificant differences (P<0.01) between
DIs in seminomas and all non-seminomas, and between seminomas and pure
non-seminomas.950 S.D. FOSSA et al.
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Figure 1 Distribution of DNA indices in testicular cancer a,
Pure seminoma with one stemline; b, Pure seminoma with two or
three stemlines; c, Non-seminoma with one stemline; d, Non-
seminoma with two or three stemlines. *, Tumours with 2
stemlines; 0, Tumours with 3 stemlines.
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Figure 2 DNA histograms of pure seminoma with one a, two b,
or three c, FCM DNA stemlines.
a broader ploidy range but the difference is not statistically
significant. More studies are needed clarify the oncogenesis of
germ cell tumours.
Extensive chromosomal aberrations as indicated by non-
diploidy and multiple DIs in a tumour are often associated
with biological aggressive of urological cancer (Tribukait et
al., 1987). Most of the highly malignant tumours display DIs
between the diploid and tetraploid range or have more than
one diploid stemline. A low DI may be the expression of
particularly extensive chromsomal changes often associated
with a higher malignant potential of a tumour. This is consis-
tent with significantly lower DIs in all non-seminomas as
compared with seminomas, the former generally being more
malignant clinically. In our study the clinical aggressiveness
Table III DIs in testicular cancer in relation to metastatic status
Seminoma Non-seminoma
No. metastases
1 stemline 28a 28
2-3 stemlines 20 14
Minimal DI 1.55b 1.44
(1.0-3.09)c (0.82-2.93)
Maximal DI 2.05 2.13
(1.57-3.33) (1.23-3.10)
Metastases present
1 stemline 10 16
2-3 stemlines 3 10
Minimal DI 1.65 1.43
(1.2-2.28) (0.77-2.68)
Maximal DI 1.73 2.63
(1.67-1.73) (2.09-3.45)
aNumber ofpatients; bMedian; cRange.
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Figure 3 DNA histograms of three pure seminomas removed
within one week from two monozygotic twins. (One twin with
bilateral tumours, the other with unilateral tumour.)
as expressed by the metastatic potential was, however, not
associated with particularly low DIs or multiplicity of the
DNA stemlines. This is in contrast to Nativ et al.'s (1989)
observations on the prognostic significance of DNA ploidy,
but is consistent with the work of Oosterhuis et al. (1989)
and Quirke et al. (1986). Our findings may be due to the
small number ofcases examined. It may also be that chromo-
somal changes not detectable by DNA FCM are more closely
related to the stage and prognosis of the testicular germ cell
tumour than DNA stemline ploidy. Bosl et al. (1989) have
shown that the presence of the isochromosome il2p may be
correlated to prognosis.
The present study and other work published so far on
DNA FCM in germ cell tumours contribute to the under-
standing of the oncogenesis of this tumour. Larger studies
should be done to correlate the clinical course of testicular
cancer with the results of DNA FCM.
This work was financially supported by the Norwegian Cancer
Society.
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